• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Use of piperacillin-tazobactam (Zosyn) likely less effective than meropenem for ceftriaxone-resistant gram-negative bacteremia

byBrittany Hasty, MDandDaniel Fisher
September 13, 2018
in Chronic Disease, Infectious Disease, Public Health
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. In this randomized controlled trial, piperacillin-tazobactam was not found to be non-inferior to meropenum for all-cause mortality at 30 days among patients with gram-negative bacteremia.

2. There was no difference in microbiological resolutions between the two antibiotics in ceftriaxone-resistant gram-negative bacteremia.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Antibiotic resistance has become an increasing concern, especially for ceftriaxone-resistant gram-negative bacilli that produce extended-spectrum beta-lactamase enzymes (ESBL). Antibiotics such piperacillin-tazobactam has been proposed as a carbapenem alternative, though it is unclear if they as effective. In this randomized, multinational trial, non-inferiority could not be established for piperacillin-tazobactam compared to meropenum in terms of all-cause mortality at 30 days. There was no difference in the time to resolutions of symptoms of infection nor in minimum inhibitory concentration (MIC) between the two groups. Among blood culture isolates, an overwhelming majority produced ESBL enzymes and nearly all were susceptible to meropenem. After the data and safety monitoring board reviewed this study in August of 2017, the decision was made to terminate the study based on harm and futility.

Efforts to discover alternatives to carbapenems should continue despite the results from this trial. Unfortunately, in this study, empiric antibiotic therapy was not dictated by study protocol and therefore could have very well influenced the outcomes from this study. Additionally, with this being a multinational study, antibiotics may have been dosed differently in some hospitals.

Click to read the study in JAMA

RELATED REPORTS

Oral gepotidacin is non-inferior to standard therapy for uncomplicated urogenital gonorrhea

2-day antibiotic non-inferior to 5-day antibiotic therapy for postoperative management of complex appendectomy

Ceftriaxone use is not associated with increased free bilirubin in term neonates with sepsis

Relevant Reading: Carbapenems versus alternative antibiotics for the treatment of bacteremia due to Enterobacteriaceae producing extended-spectrum beta-lactamases: a systematic review and meta-analysis

In-Depth [randomized controlled trial]: This study recruited eligible patients from 26 hospitals in 9 countries from February 2014 to July 2017. Eligible patients were those having either E coli or Klebsiella bacteremia. Patients were randomized in a 1:1 ratio to receive either piperacillin-tazobactam or meropenem. The primary outcome was all-cause mortality at 30-days. A total of 1,646 patients were screened for eligibility during the study period and 379 patients were enrolled to receive either piperacillin-tazobactam (n=187) or meropenem (n=191). There were no differences in baseline characteristics of the two groups. Overall, 30 patients met the primary outcome of all-cause mortality at 30 days, 23 in the piperacillin-tazobactam group and 7 meropenem in the meropenem group (risk difference 8.6%; p = 0.90 for non-inferiority). There was no difference in time to resolution of signs of infection between the two groups (3 vs. 2 (IQR 1,5); p = 0.18). A total of 306 resulting blood cultures were available from the primary outcome population (n=266 E coli; n=40 Klebsiella). 99.7% of isolates were susceptible to meropenem and extended spectrum beta-lactamase (ESBL) production was discovered in 86% of isolates. The study was terminated on August 10, 2017 due to reasons of harm and futility. 

Image: PD

©2018 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

 

Tags: ceftriaxonezosyn
Previous Post

2 Minute Medicine Rewind September 10, 2018

Next Post

2 Minute Medicine Rewind September 17, 2018

RelatedReports

Nearly Half of All Pediatric Buprenorphine Exposures Result in Hospitalization
Infectious Disease

Oral gepotidacin is non-inferior to standard therapy for uncomplicated urogenital gonorrhea

May 28, 2025
Unenhanced magnetic resonance imaging highly sensitive and specific for acute appendicitis
Gastroenterology

2-day antibiotic non-inferior to 5-day antibiotic therapy for postoperative management of complex appendectomy

February 14, 2023
Increasing C-section room temperature linked to reduced neonatal, maternal hypothermia
Infectious Disease

Ceftriaxone use is not associated with increased free bilirubin in term neonates with sepsis

November 22, 2022
Patient Basics: Middle-Ear Infection (Otitis Media)
ENT

Tympanostomy tubes not superior to medical management for recurrent acute otitis media

June 7, 2021
Next Post
Imatinib safe and effective as long-term treatment for chronic myeloid leukemia: The IRIS trial

2 Minute Medicine Rewind September 17, 2018

Development of a risk index for colorectal cancer screening

Tailoring fecal immunochemical tests positivity thresholds by age and sex may help to optimize colorectal cancer screening

Increased diabetes risk observed in gout patients

Quarterly canakinumab administration associated with significantly reduced risk for gout attacks

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Tarlatamab Improves Survival in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
  • Large language models show potential to provide feedback on research papers on a large-scale
  • #VisualAbstract: Elinzanetant Effectively Reduces Vasomotor Symptoms from Endocrine Therapy for Breast Cancer
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.